# Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

> **NCT05403333** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 61 (estimated)

## Conditions studied

- Breast Neoplasms
- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** utidelone

## Key facts

- **NCT ID:** NCT05403333
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-10
- **Primary completion:** 2023-03-09
- **Final completion:** 2025-03-09
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2022-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05403333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05403333, "Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05403333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*